72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)
Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.
Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.
Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.
Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.
She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.
Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.
Diversity, Equity, Inclusion and Accessibility
I stand firmly committed to diversity, equity, inclusion, and justice as a core value of my professional and personal life. I have a strong commitment to making a difference to people from underprivileged and marginalized communities. I strive to bridge access to the most cutting-edge diagnostic modalities and treatments for members of all underrepresented groups—e.g., ethnic, racial, religious, and sexual minorities, among others.
I also support diversity and equity through my research efforts, by studying racial and ethnic inequalities that are pervasive within the field of medicine. In particular, I am struck by the low representation of minorities in clinical trials, despite having a disproportionately higher risk of certain diseases. I mentored a fellow to conduct a study investigating racial and ethnic disparities in a rare plasma cell disorder called AL amyloidosis, and found that differences in health outcomes among minorities were largely explained by lower educational level and later recognition of disease, rather than race and ethnicity itself. We concluded that, in order to mitigate disparities in this rare disease, earlier disease detection and concerted efforts to reduce economic and/or language barriers are key.
My influence extends beyond the groundbreaking and paradigm-shifting work in the field of amyloidosis. In addition to my scientific achievements, I have an interest in working in charity organizations. I help cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteer regularly at “Cradles to Crayons” charity, non-profit organization. I consistently seek opportunities to understand, respect and serve communities in need.
Boston University Chobanian & Avedisian School of Medicine
BU-BMC Cancer Center
Boston Medical Center
Stem Cell Transplantation Program
Hematology & Medical Oncology
International Society of Amyloidosis
Amyloidosis Research Consortium
Amyloid: The Journal of Protein Folding disorders
SPORE in Multiple Myeloma
06/01/2021 - 05/31/2023 (Key Person / Mentor)Dana-Farber Cancer Institute NIH NCI5P50CA100707-19
Evaluating Plasma Neurofilament Light Chain as an Early Biomarker for Polyneuropathy in V122I Hereditary Transthyretin Amyloidosis
01/01/2022 - 12/31/2022 (Key Person / Mentor)
PI: K. H. Vincent Lau, MDAmyloidosis Foundation
A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2022 (PI)Millennium Pharmaceuticals, Inc.
Defining a molecular signature of cardiac tissue dysfunction in systemic immunoglobulin light-chain amyloidosis
07/01/2020 - 06/30/2022 (Key Person / Mentor)
PI: Camille Edwards, MDAmerican Society of Hematology
A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2021 (PI)Celgene Corporation
Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Co-Investigator)The Brigham and Women's Hospital, Inc. NIH NHLBI5R01HL130563-04
A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)Academic Myeloma Consortium
Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (Subcontract PI)Trustees Of Columbia University In The City Of New York Cephalon, Inc
A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)Onclave Therapeutics Limited, d/b/a Prothena Therapeutics Limited
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)Millennium Pharmaceuticals, Inc.
Showing 10 of 17 results.
Show All Results
11/17/2017 - 11/17/2026 (PI)Janssen Research and Development, LLC
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
05/19/2022 - 05/18/2025 (PI)Janssen Research and Development, LLC
CAEL-101 301: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/22/2024 (PI)Caelum Biosciences, Inc.
CAEL-101 302: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/22/2024 (PI)Caelum Biosciences, Inc.
NEOD001-301: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
06/23/2021 - 06/22/2024 (PI)Prothena Biosciences Limited
DARATUMUMAB, POMALIDOMIDE AND DEXAMETHASONE (DPd) IN RELAPSED/ REFRACTORY LIGHT CHAIN AMYLOIDOSIS PATIENTS PREVIOUSLY EXPOSED TO DARATUMUMAB
07/23/2020 - 01/22/2024 (PI)Weill Cornell Medical College Janssen Scientific A
DFCI 19-291: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone…
12/23/2019 - 12/22/2023 (PI)Dana Farber Cancer Institute Millennium Pharmaceu
STI-6129-001: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
12/01/2020 - 11/30/2023 (PI)Sorrento Therapeutics, Inc.
A Phase II randomized single-blind study to evaluate the activity and safety of low dose oral…
04/23/2020 - 04/22/2023 (PI)Karyopharm Therapeutics Inc.
Oncopeptides: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL…
11/21/2019 - 11/20/2022 (PI)Oncopeptides AB
Showing 10 of 16 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 236 results.
Gustine JN, Staron A, Mendelson L, Joshi T, Gopal DM, Siddiqi OK, Ruberg FL, Sanchorawala V. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv. 2023 Oct 24; 7(20):6080-6091.View Related Profiles. PMID: 37581513
Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, Liedtke M, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023 Oct 05; 142(14):1208-1218. PMID: 37366170; PMCID: PMC10644097; DOI: 10.1182/blood.2022019406;
Sarosiek S, Lee MH, Doros G, Edwards CV, Quillen K, Brauneis D, Shelton AC, Sanchorawala V, Sloan JM. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study. Transplant Cell Ther. 2023 Aug 20.View Related Profiles. PMID: 37607644
Ghosh S, Villacorta-Martin C, Lindstrom-Vautrin J, Kenney D, Golden CS, Edwards CV, Sanchorawala V, Connors LH, Giadone RM, Murphy GJ. Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures. Amyloid. 2023 Jul 13; 1-15.View Related Profiles. PMID: 37439769; DOI: 10.1080/13506129.2023.2224494;
Adebayo AL, Rowan KE, Sanchorawala V, Boedicker MN, Boedicker DD. Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients' narratives on medical students' knowledge, attitudes, and behavioral intent. MedEdPublish (2016). 2023; 13:32. PMID: 37753389; PMCID: PMC10518845; DOI: 10.12688/mep.19631.1;
Rizio AA, White MK, D'Souza A, Hsu K, Schmitt P, Quock TP, Signorovitch J, Lousada I, Sanchorawala V. Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group. Patient Relat Outcome Meas. 2023; 14:153-169. PMID: 37229285; PMCID: PMC10202704; DOI: 10.2147/PROM.S399658;
Mendelson L, Prokaeva T, Lau KHV, Sanchorawala V, McCausland K, Spencer B, Dasari S, McPhail ED, Kaku MC. Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions. Amyloid. 2023 May 04; 1-7.View Related Profiles. PMID: 37140928
Sanchorawala V. Eureka Moment-Innovation Comes of an Age in Light Chain Amyloidosis. JCO Oncol Pract. 2023 May; 19(5):276-277. PMID: 36854072
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
2015 Research mentor award
2015 Schwartz Center for Compassionate Healthcare:
Compassionate Caregiver Award
2011 Research Mentoring Award nomination
2011 Schwartz Center for Compassionate Healthcare:
Compassionate Caregiver Award
2007-2009 Robert Dawson Evans Clinician Award
Mortimer M. Bortin Award for best abstract